短效雄激素治疗迟发性性腺功能减退的安全性研究

目的：探讨短效雄激素长程替代治疗迟发性性腺功能减退（LOH）的安全性。方法选取2007年3月至2012年3月于我院男科门诊就诊的1086例男性迟发性性腺功能减退（LOH）患者作为试验组，另选择同期1086例单纯前列腺炎及前列腺增生症患者作为对照，试验组患者行短效雄激素长程替代治疗，对照组患者采用常规治疗，比较两组患者治疗前后前列腺特异抗原（PSA）变发率、膀胱出口梗阻（BOO）发生率、肝损发生率及红细胞比容（HCT）病理增高发生率的差异情况。结果治疗后试验组患者PSA增高变发率为8.5%，对照组为9.9%，其差异无统计学意义（χ^2=1.24，P〉0.05）。试验组患者BOO发生率为4.2%，对照组为5.7%，差异无统计学意义（χ^2=2.49，P〉0.05）。试验组患者转氨酶（ALT）增高发生率为1.2%，对照组为1.9%，差异无统计学意义（χ^2=1.91， P〉0.05）。试验组患者HCT增高发生率仅为0.092%，对照组患者HCT增高发生率为0.184%，差异无统计学意义（χ^2=0.3338，P=0.5634）。结论仿生理节律小剂量短效雄激素长程补充治疗LOH具有较好的安全性。

Study of the safety about treating LOH with short efficacious androgen

Objective To study the safety about treating LOH with short efficacious androgen in long term. Methods A total of 1 086 cases of LOH were investigated and another 1 086 cases of prostate hypertrophy were also selected in same period. The experimental group was treated with short acting testosterone long-range replacement therapy, and the control group was treated with conventional therapy. The happening rates of PSA increasing, BOO increasing, liver damage and HCT increasing were observed. Results The occurrence rate of elevated PSA in patients in test group was 8.5%, while that in the control group was 9.9%, and the difference was not statistically significant （χ^2=1.24, P〉0.05）. The occurrence rate of BOO in the experimental group was higher than that in the control group （χ^2=2.49, P〉0.05）. The elevated ALT occurred inpatients in experimental group was 1.2%, while that in the con-trol group was 2.0%, and the difference was not statistically significant （χ^2=1.91, P〉0.05）. The occurrence rate of HCT increase in the experimental group was 0.092%, while that in the control group was 0.184%（χ^2=0.3338, P=0.5634）. Conclusion The treatment for LOH with small dose short efficacious androgen in long term is safe.